Nippon India Pharma Fund Direct Growth
Nippon India Pharma Fund Direct Growth: NAV ₹660.72, 3Y return 17.81%, 5Y 15.23%, AUM ₹9,279 Cr, expense ratio 0.98%, iNVESTT rating 4/5. Returns vs index, rolling returns, holdings, Direct vs Regular and peers, by a SEBI Registered Research Analyst.
Key facts
- NAV
- ₹660.7235 (19 Nov 2026)
- 1-year return
- 14.06%
- 3-year return (CAGR)
- 17.81%
- 5-year return (CAGR)
- 15.23%
- Fund size (AUM)
- ₹9,279 Cr
- Expense ratio
- 0.98%
- Exit load
- 1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.
- Minimum investment
- Rs. 5,000 and in multiples of Re.1 thereafter
- Category
- Sectoral Fund
- Benchmark
- BSE Healthcare TRI
- Riskometer
- Very High Risk
- Fund manager
- Sailesh Raj Bhan
- Launch date
- 10 May 2004
- iNVESTT rating
- 4 out of 5
Frequently asked questions
What is the NAV of Nippon India Pharma Fund Direct Growth today?
The NAV of Nippon India Pharma Fund Direct Growth is ₹660.7235 as of 19 Nov 2026.
What are the returns of Nippon India Pharma Fund Direct Growth?
14.06% over 1 year, 17.81% a year over 3 years, 15.23% a year over 5 years. Past returns do not guarantee future returns; compare them with the benchmark and rolling returns on this page.
What is the expense ratio of Nippon India Pharma Fund Direct Growth?
The expense ratio (TER) is 0.98% a year.
What is the AUM (fund size) of Nippon India Pharma Fund Direct Growth?
Nippon India Pharma Fund Direct Growth manages ₹9,279 Cr.
Is there an exit load on Nippon India Pharma Fund Direct Growth?
Exit load: 1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter..
How risky is Nippon India Pharma Fund Direct Growth?
Its SEBI riskometer is "Very High Risk" and it is in the Sectoral Fund category.
What is the benchmark of Nippon India Pharma Fund Direct Growth?
The benchmark is BSE Healthcare TRI. This page compares the fund with its benchmark's total-return index (TRI).
What is the iNVESTT rating of Nippon India Pharma Fund Direct Growth?
4 out of 5. iNVESTT rating: where the fund ranks in its category over 1, 3 and 5 years (3 and 5 years count most). Top fifth = 5 stars. A past-performance measure, not a recommendation.
Research by iNVESTT, a SEBI Registered Research Analyst (INH000010858). Data from AMFI. Mutual fund investments are subject to market risks; past performance does not guarantee future returns.